224 related articles for article (PubMed ID: 20868758)
1. Comparison of the NIDS® rapid assay with ELISA methods in immunogenicity testing of two biotherapeutics.
Pan J; Small T; Qin D; Li S; Wang L; Chen D; Pauley C; Verch T; Kaplanski C; Bakhtiar R; Vallejo YR; Yin R
J Pharmacol Toxicol Methods; 2011; 63(2):150-9. PubMed ID: 20868758
[TBL] [Abstract][Full Text] [Related]
2. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers.
Liu Y; Reidler H; Pan J; Milunic D; Qin D; Chen D; Vallejo YR; Yin R
J Pharmacol Toxicol Methods; 2011; 64(3):238-45. PubMed ID: 21827863
[TBL] [Abstract][Full Text] [Related]
3. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
4. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
Li J; Schantz A; Schwegler M; Shankar G
J Pharm Biomed Anal; 2011 Jan; 54(2):286-94. PubMed ID: 20869832
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
[TBL] [Abstract][Full Text] [Related]
6. A novel homogeneous Biotin-digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum.
Qiu ZJ; Ying Y; Fox M; Peng K; Lewin-Koh SC; Coleman D; Good J; Lowe J; Rahman A; Yang J; Jiang J; Quarmby V; Song A
J Immunol Methods; 2010 Oct; 362(1-2):101-11. PubMed ID: 20868690
[TBL] [Abstract][Full Text] [Related]
7. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
[TBL] [Abstract][Full Text] [Related]
8. Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies.
Wang SJ; Wu ST; Gokemeijer J; Fura A; Krishna M; Morin P; Chen G; Price K; Wang-Iverson D; Olah T; Weiner R; Tymiak A; Jemal M
Anal Bioanal Chem; 2012 Jan; 402(3):1229-39. PubMed ID: 22130720
[TBL] [Abstract][Full Text] [Related]
9. Epitope characterization of the ADA response directed against a targeted immunocytokine.
Stubenrauch K; Künzel C; Vogel R; Tuerck D; Schick E; Heinrich J
J Pharm Biomed Anal; 2015 Oct; 114():296-304. PubMed ID: 26093509
[TBL] [Abstract][Full Text] [Related]
10. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
[TBL] [Abstract][Full Text] [Related]
11. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients.
Bloem K; van Leeuwen A; Verbeek G; Nurmohamed MT; Wolbink GJ; van der Kleij D; Rispens T
J Immunol Methods; 2015 Mar; 418():29-38. PubMed ID: 25637408
[TBL] [Abstract][Full Text] [Related]
12. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA.
Smith HW; Butterfield A; Sun D
Regul Toxicol Pharmacol; 2007 Dec; 49(3):230-7. PubMed ID: 17869396
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.
Wang SL; Ohrmund L; Hauenstein S; Salbato J; Reddy R; Monk P; Lockton S; Ling N; Singh S
J Immunol Methods; 2012 Aug; 382(1-2):177-88. PubMed ID: 22691619
[TBL] [Abstract][Full Text] [Related]
14.
Ubah OC; Porter AJ; Barelle CJ
J Immunol Res; 2020; 2020():7283239. PubMed ID: 32090129
[TBL] [Abstract][Full Text] [Related]
15. Strategies to estimate and improve drug tolerance in anti-drug antibody assays.
Bütikofer L; Lemaillet G; Faust H
Bioanalysis; 2012 Aug; 4(16):1999-2012. PubMed ID: 22946916
[TBL] [Abstract][Full Text] [Related]
16. Conversion of a capture ELISA to a Luminex xMAP assay using a multiplex antibody screening method.
Baker HN; Murphy R; Lopez E; Garcia C
J Vis Exp; 2012 Jul; (65):. PubMed ID: 22806215
[TBL] [Abstract][Full Text] [Related]
17. Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore.
Sickert D; Kroeger K; Zickler C; Chokote E; Winkler B; Grenet JM; Legay F; Zaar A
J Immunol Methods; 2008 May; 334(1-2):29-36. PubMed ID: 18304570
[TBL] [Abstract][Full Text] [Related]
18. Application of a Plug-and-Play Immunogenicity Assay in Cynomolgus Monkey Serum for ADCs at Early Stages of Drug Development.
Carrasco-Triguero M; Davis H; Zhu Y; Coleman D; Nazzal D; Vu P; Kaur S
J Immunol Res; 2016; 2016():2618575. PubMed ID: 27092313
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
[TBL] [Abstract][Full Text] [Related]
20. Development of a qualitative indirect ELISA for the measurement of rabies virus-specific antibodies from vaccinated dogs and cats.
Cliquet F; McElhinney LM; Servat A; Boucher JM; Lowings JP; Goddard T; Mansfield KL; Fooks AR
J Virol Methods; 2004 Apr; 117(1):1-8. PubMed ID: 15019254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
